News Search Results
Jun 16, 2026, 12:46 ET Joseph D'Antonio III Joins Elder Law Department at Rubin Rudman
Rubin Rudman serves national and international companies, including large public companies and closely held businesses; real estate developers; biotechnology, pharmaceutical and medical device makers; hospitality companies; regulated industries, public entities and municipalities; insurance companies
More news about: Rubin Rudman
Jun 16, 2026, 12:39 ET Secondary Antibodies Market Size to Reach USD 2.97 Billion by 2033, Growing at a 7.9% CAGR as Standardized Immunoassay Workflows and Biomarker Research Accelerate Global Demand: Verified Market Research
traceability and standardization, particularly among pharmaceutical and biotechnology companies requiring clear reagent qualification pathways.Santa Cruz BiotechnologySanta Cruz Biotechnology is positioned as a broad secondary antibody supplier with wide target coverage
More news about: Verified Market Research
Jun 16, 2026, 11:01 ET Jetstream Venture Fund Secures Position in Rejuvenate Bio, Investing Alongside Industry Giant Merck
treatment from reactive symptom management to cellular-level resolution. Utilizing a proprietary, non-genome-editing gene therapy platform, the biotechnology company develops groundbreaking, single-dose treatments that provide lifelong, systemic benefits.Its current pipeline addresses high-prevalence
More news about: Jetstream Venture Fund
Jun 16, 2026, 10:30 ET Biosimulation Market worth $9.24 billion by 2031 | MarketsandMarkets™
dominance can be attributed to the need for stringent data security, intellectual property protection, and regulatory compliance in pharmaceutical and biotechnology research. Biosimulation workflows often involve highly sensitive preclinical, clinical, and proprietary molecular data, prompting many organizations
More news about: MarketsandMarkets
Jun 16, 2026, 10:03 ET Angel Yeast Chairman Reflects on 40 Years of Bringing Yeast to Millions of Households Worldwide
yeast-derived ingredients, ranging from savory yeast extracts to yeast protein for nutrition applications. In yeast extracts, Angel Yeast applies biotechnology to help food manufacturers meet consumer demand for products that balance taste and nutrition. In yeast protein, its Angeopro product contains more
More news about: Angel Yeast
Jun 16, 2026, 10:01 ET Rapid Microbiology Testing Market worth $9.00 billion by 2031 | MarketsandMarkets™
contamination tracking, and decision-making capabilities. Increasing demand for rapid and reliable microbiological quality control in pharmaceutical & biotechnology companies, food & beverage manufacturers, and environmental testing laboratories is driving the adoption of advanced rapid microbiology testing
More news about: MarketsandMarkets
Jun 16, 2026, 09:30 ET 4E Therapeutics Acquired by Lilly to Advance Non-Opioid Approach to Chronic Pain
source. 4E's medicinal chemistry and drug development has been led by James Sahn, Vice President of Drug Development. T. Craig Benson, a serial biotechnology and life sciences entrepreneur, has led 4E from its founding as CEO.
More news about: 4E Therapeutics
Jun 16, 2026, 09:30 ET Clinical Trials on Alzheimer's Disease Conference and Alzheimer's Drug Discovery Foundation Partner to Advance Emerging Biotech Innovation at CTAD 2026
unique ability to convene scientists, investors, pharmaceutical leaders, and philanthropists. The initiative is designed to spotlight promising biotechnology companies developing next-generation therapeutics, diagnostics, and technologies for Alzheimer's and related dementias.
More news about: Alzheimer's Drug Discovery Foundation
Jun 16, 2026, 09:05 ET BioMarin Announces New Three-Year VOXZOGO® (vosoritide) Data in Hypochondroplasia and BMN 333 Early Results at ENDO 2026
Patient Information.About BioMarinBioMarin is a leading, global rare disease biotechnology company focused on delivering medicines for people living with genetically defined conditions. Founded in 1997, the San Rafael, California-based
More news about: BioMarin Pharmaceutical Inc.
Jun 16, 2026, 09:04 ET Dr. Leen Kawas, CEO of EIT Pharma, Highlights on EASL Congress 2026
her own companies, she serves on the boards of and advises several biotechnology ventures, partnering with founders to translate early-stage science into enduring, scalable enterprises. She is a vocal advocate for women in biotechnology, actively working to expand access and opportunity for female talent
More news about: EIT Pharma
Jun 16, 2026, 09:01 ET Phenomix Sciences Launches MyPhenome® Test Directly to Patients to Help Guide Weight Loss Treatment Based on Biology
Phenomix Sciences (Phenomix), the first commercial precision obesity medicine biotechnology company, today announced that patients can now order the
More news about: Phenomix Sciences
Jun 16, 2026, 09:00 ET Neurophet Showcases 'Brain Imaging AI Solutions' at BIO USA, Accelerates Global Business Development Collaborations
and evaluating therapeutic outcomes after treatment.Neurophet will operate a booth at the Korea Pavilion jointly organized by the Korea Biotechnology Industry Organization and the Korea Trade-Investment Promotion Agency (KOTRA), where it will showcase Neurophet AQUA AD Plus, along with Neurophet
More news about: Neurophet
Jun 16, 2026, 08:43 ET TriasMD Unveils New Executive Leadership Team to Lead its Next Chapter of Growth
expansion.Joey Dambroso joins as Controller, bringing more than 15 years of experience across public and private companies spanning healthcare, biotechnology, technology, and logistics. He has held finance and accounting leadership roles at Amazon, 4D Molecular Therapeutics, and Lineage, following early-career
More news about: TriasMD
Jun 16, 2026, 08:13 ET Large-Aperture XY Motion Stage Built for Semiconductor Automation
large 360 × 360 mm open aperture and is optimized for semiconductor inspection, photonics alignment, metrology, imaging, laser micro-processing, biotechnology, microscopy, precision assembly, and advanced automation systems.
More news about: Physik Instrumente (PI)
Jun 16, 2026, 08:02 ET Lakewood-Amedex Biotherapeutics to Present at Life Sciences Virtual Investor Forum
Lakewood-Amedex Biotherapeutics Inc., (NASDAQ: LABT, the "Company"), a clinical-stage biotechnology company advancing a novel class of potent, fast-acting, broad-spectrum antimicrobials for infectious diseases called the Bisphosphocin®
More news about: Lakewood-Amedex Biotherapeutics Inc.
Jun 16, 2026, 08:00 ET Matica Biotechnology and Cirsium Biosciences Announce Adoption of Matica Open Access Platform to Accelerate Flexible AAV Manufacturing
June 16, 2026 /PRNewswire/ -- **Matica Biotechnology, Inc. (Matica Bio), a leading contract development and manufacturing organization (CDMO) specializing in viral vector production, and Cirsium Biosciences ("Cirsium"), a biotechnology company leveraging novel plant science to reimagine
More news about: Matica Biotechnology, Inc.
Jun 16, 2026, 08:00 ET ProJenX Announces a Development Update for Prosetin, a First-in-Class, CNS-Penetrant MAP4K Inhibitor
meetingNEW YORK, June 16, 2026 /PRNewswire/ -- ProJenX, a clinical stage biotechnology company developing novel, targeted, brain-penetrant therapies for the treatment of amyotrophic lateral sclerosis (ALS) and other debilitating brain
More news about: ProJenX
Jun 16, 2026, 08:00 ET Mighty Therapeutics, Formerly Stealth BioTherapeutics, Announces New Name Honoring the Mitochondrial Disease Community
Stealth BioTherapeutics Holdings Inc., a commercial-stage biotechnology company focused on the discovery, development, and commercialization of novel therapies for rare and age-related diseases driven by mitochondrial
More news about: Stealth BioTherapeutics Inc.
Jun 16, 2026, 08:00 ET Verge Labs Unveils vBx: A Breakthrough Foundation Model for Precision Neurology
on partners' clinical trial datasets. Earlier this month the company announced its first platform partnership, a CNS collaboration with Tenacia Biotechnology. "If you have a trial that failed in a mixed population, or you're designing one now, we want to run the virtual biopsy on it," said Zhang.Partners
More news about: Verge Labs
Jun 16, 2026, 07:30 ET SpliSense Secures Up to $13 Million from the Cystic Fibrosis Foundation to Advance Phase 2b Study of SPL84 for Cystic Fibrosis
June 16, 2026 /PRNewswire/ -- SpliSense, a clinical-stage biotechnology company developing transformative RNA-based therapies for pulmonary diseases, today announced that it has entered into a funding agreement with
More news about: SpliSense
Jun 16, 2026, 07:00 ET Cizzle Bio Announces Laboratory Validation of CIZ1B Biomarker Blood Test for Early Lung Cancer at OmniHealth Diagnostics
DALLAS, June 16, 2026 /PRNewswire/ -- Cizzle Bio, Inc., a Texas-based biotechnology company advancing biomarker blood tests for early detection of lung and gastric cancers, today announced the laboratory validation of its proprietary
More news about: Cizzle Bio
Jun 16, 2026, 06:00 ET Waterdrop Inc. Announces First Quarter 2026 Unaudited Financial Results
clinical trial solution income represents the service income earned from our customers mainly including biopharmaceutical companies and leading biotechnology companies. We match qualified and suitable patients for enrollment in clinical trials for our customers and generate digital clinical trial solution
More news about: Waterdrop Inc.
Jun 16, 2026, 05:36 ET Bio Vanillin Market to Reach USD 485.5 Million by 2036 Amid Rising Demand for Natural Flavors and Clean-Label Food Ingredients | Future Market Insights
ingredients, rising consumer preference for natural flavors, expanding applications in premium food products, and growing investments in sustainable biotechnology-driven flavor production.Bio vanillin has emerged as a high-value flavor ingredient that offers manufacturers a natural alternative to synthetic
More news about: Future Market Insights
Jun 16, 2026, 03:52 ET Innovative Molecules Expands Virology Pipeline with Novel EBV Antiviral Program
indications where current treatment options remain limited.About Innovative MoleculesInnovative Molecules GmbH is a clinical-stage biotechnology company based in Munich, Germany, focused on the development of differentiated antiviral therapies for herpesvirus-associated diseases. The company
More news about: Innovative Molecules GmbH
Jun 16, 2026, 03:46 ET Innovative Molecules Expands Virology Pipeline with Novel EBV Antiviral Program
options remain limited.About Innovative MoleculesInnovative Molecules GmbH is a clinical-stage biotechnology company based in Munich, Germany, focused on the development of differentiated antiviral therapies for herpesvirus-associated diseases. The company
More news about: Innovative Molecules GmbH